gene mutations responsible for NARP syndrome in humans and uses thereof for screening for medicaments
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jul 3, 2012
Grant Date -
Jan 28, 2010
app pub date -
May 3, 2007
filing date -
May 3, 2006
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
Modified yeast cells comprising at least one mutation of the tryptophan 136 (W136), leucine 183 (L183), or leucine 247 (L247) codon of the mitochondrial ATP6 gene, responsible for NARP syndrome in humans and uses thereof for screening for medicaments that act against mitochondrial pathologies involving a deficiency in ATP production via the oxidative phosphorylation pathway, such as NARP syndrome.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully